Added benefit of the fixed combination of dapagliflozin and metformin is not proven
The fixed combination of the drugs dapagliflozin and metformin (trade name: Xigduo) has been approved since January 2014 for adults with type 2 diabetes in whom diet and exercise do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) now examined whether this new drug combination offers an added benefit over the appropriate comparator therapy. No such added benefit can be derived from the dossier, however, ...









